You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

DILANTIN-125 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Dilantin-125 patents expire, and when can generic versions of Dilantin-125 launch?

Dilantin-125 is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in DILANTIN-125 is phenytoin. There are twenty-one drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the phenytoin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Dilantin-125

A generic version of DILANTIN-125 was approved as phenytoin by TARO on March 8th, 2004.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DILANTIN-125?
  • What are the global sales for DILANTIN-125?
  • What is Average Wholesale Price for DILANTIN-125?
Summary for DILANTIN-125
Drug patent expirations by year for DILANTIN-125
Drug Prices for DILANTIN-125

See drug prices for DILANTIN-125

Drug Sales Revenue Trends for DILANTIN-125

See drug sales revenues for DILANTIN-125

Recent Clinical Trials for DILANTIN-125

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bristol-Myers SquibbPhase 1
UCB Pharma GmbHPhase 4
Lawson Health Research InstitutePhase 4

See all DILANTIN-125 clinical trials

US Patents and Regulatory Information for DILANTIN-125

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viatris DILANTIN-125 phenytoin SUSPENSION;ORAL 008762-001 Approved Prior to Jan 1, 1982 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.